GHRP-6 (growth hormone-releasing peptide-6) and ipamorelin are both growth hormone secretagogues (GHS) that stimulate GH release through ghrelin receptor (GHSR1a) agonism. Despite sharing the same primary receptor, they differ markedly in receptor selectivity, off-target hormone effects, and clinical tolerability. Understanding these distinctions is essential for informed secretagogue selection.
Molecular Profiles
Section titled “Molecular Profiles”GHRP-6
Section titled “GHRP-6”GHRP-6 is a synthetic hexapeptide analogue of enkephalin, one of the first synthetic GH secretagogues developed:
- Sequence: His-D-Trp-Ala-Trp-D-Phe-Lys-NH₂
- Molecular weight: ~873 Da
- Receptor: GHSR1a (primary); ghrelin receptor partial agonist
- Selectivity: Non-selective — activates GHSR1a, also binds GHRH receptor and CRF receptors
- Half-life: ~20–30 minutes
Ipamorelin
Section titled “Ipamorelin”Ipamorelin is a synthetic pentapeptide derived from GHRP-1, engineered for enhanced GHSR1a selectivity:
- Sequence: Aib-His-D-2-Nal-D-Phe-Lys-NH₂
- Molecular weight: ~712 Da
- Receptor: GHSR1a (highly selective)
- Selectivity: Selective — minimal activity at other GHS binding sites
- Half-life: ~2 hours (longer than GHRP-6)
Receptor Selectivity and Off-Target Effects
Section titled “Receptor Selectivity and Off-Target Effects”GHRP-6: Non-Selective Agonism
Section titled “GHRP-6: Non-Selective Agonism”GHRP-6’s lack of selectivity produces multiple off-target endocrine effects:
- Cortisol elevation: GHRP-6 activates CRF receptors in the hypothalamus and pituitary, stimulating ACTH release and subsequent cortisol production. Cortisol increases of 30–50% above baseline are common.
- Prolactin elevation: GHRP-6 stimulates prolactin release through direct pituitary action and serotonergic pathways. Prolactin increases of 50–100% are typical.
- Aldosterone stimulation: GHRP-6 activates the renin-angiotensin-aldosterone system (RAAS), producing fluid retention and edema.
- ACTH elevation: Direct stimulation of corticotrophs produces ACTH increases of 40–80%.
- FSH/LH effects: Minimal direct effects on gonadotropins, though cortisol elevation may indirectly suppress GnRH pulsatility.
Ipamorelin: Selective Agonism
Section titled “Ipamorelin: Selective Agonism”Ipamorelin’s engineered selectivity minimizes off-target endocrine disruption:
- Cortisol: No significant elevation — ipamorelin does not activate CRF receptors. Cortisol levels remain at baseline throughout treatment.
- Prolactin: Minimal elevation — ipamorelin does not stimulate lactotrophs. Prolactin increases are generally <10% above baseline.
- Aldosterone: No significant stimulation — RAAS remains unaffected.
- ACTH: No direct stimulation — ACTH levels remain at baseline.
Comparative Side Effect Profiles
Section titled “Comparative Side Effect Profiles”| Side Effect | GHRP-6 | Ipamorelin |
|---|---|---|
| Cortisol elevation | 30–50% ↑ | None |
| Prolactin elevation | 50–100% ↑ | <10% ↑ |
| ACTH elevation | 40–80% ↑ | None |
| Aldosterone stimulation | Yes | No |
| Appetite stimulation | Very strong | Moderate |
| Flushing | Common (30–40%) | Uncommon (5–10%) |
| Injection site reactions | Common (15–20%) | Common (15–20%) |
| Hunger/cravings | Severe | Mild |
| Headache | Common (20–30%) | Uncommon (10–15%) |
| Joint pain | Uncommon | Common (10–20%) |
| Water retention | Moderate-severe | Mild |
| Fatigue | Uncommon | Common (10–15%) |
| Tingling/paresthesia | Common (10–20%) | Uncommon (5%) |
Appetite Stimulation: A Key Differentiator
Section titled “Appetite Stimulation: A Key Differentiator”GHRP-6: Potent Orexigenic Effects
Section titled “GHRP-6: Potent Orexigenic Effects”GHRP-6 is one of the most potent appetite stimulants among GH secretagogues. The mechanism involves:
- Hypothalamic NPY/Y1 receptor activation: GHRP-6 stimulates neuropeptide Y (NPY) neurons in the arcuate nucleus, directly activating feeding circuits.
- Ghrelin pathway mimicry: As a ghrelin receptor agonist, GHRP-6 activates the same orexigenic pathways as endogenous ghrelin.
- Serotonergic modulation: GHRP-6’s affinity for 5-HT receptors may contribute to appetite effects.
Patients report intense hunger within 15–30 minutes of injection, often described as “uncontrollable” or “primal.” This effect can be advantageous for underweight patients but problematic for those seeking body composition improvement.
Ipamorelin: Moderate Appetite Effects
Section titled “Ipamorelin: Moderate Appetite Effects”Ipamorelin produces appetite stimulation, but significantly less than GHRP-6:
- Hunger onset is more gradual (30–60 minutes).
- Intensity is moderate — comparable to mild fasting, not the acute drive seen with GHRP-6.
- The effect diminishes with chronic use in many patients.
Clinical Implications
Section titled “Clinical Implications”When GHRP-6 May Be Preferred
Section titled “When GHRP-6 May Be Preferred”Despite its side effect profile, GHRP-6’s potency and appetite stimulation offer advantages in specific contexts:
- Severe GH deficiency: GHRP-6’s greater GH release may benefit patients with profound somatotroph dysfunction.
- Cachexia/wasting: Appetite stimulation is therapeutically valuable in cancer cachexia, HIV wasting, or post-surgical recovery.
- Short-term protocols: GHRP-6’s strong effects are tolerable in short courses (4–8 weeks).
When Ipamorelin Is Preferred
Section titled “When Ipamorelin Is Preferred”Ipamorelin’s selectivity makes it preferable for most clinical applications:
- Chronic GH replacement: Minimal endocrine disruption supports long-term use.
- Body composition improvement: Lower appetite stimulation reduces caloric excess.
- Sleep quality improvement: Ipamorelin’s effects on slow-wave sleep (SWS) are preserved without cortisol disruption.
- Patients sensitive to side effects: Better tolerability improves adherence.
Hormonal Monitoring Requirements
Section titled “Hormonal Monitoring Requirements”| Parameter | GHRP-6 | Ipamorelin |
|---|---|---|
| Cortisol monitoring | Essential | Unnecessary |
| Prolactin monitoring | Essential | Unnecessary |
| IGF-1 monitoring | Recommended | Recommended |
| Thyroid function | Recommended | Unnecessary |
| Glucose monitoring | Recommended | Recommended |
| Fluid balance | Monitor | Unnecessary |
GHRP-6 requires comprehensive hormonal monitoring due to its multi-axis endocrine effects. Ipamorelin’s selectivity reduces the monitoring burden to IGF-1 and glucose — the essential markers for GH therapy.
Summary
Section titled “Summary”GHRP-6 and ipamorelin share GHSR1a as their primary target but differ fundamentally in receptor selectivity and off-target effects. GHRP-6’s non-selective agonism produces potent GH release accompanied by significant cortisol, prolactin, and aldosterone elevation — alongside intense appetite stimulation. Ipamorelin’s engineered selectivity delivers clean GH stimulation without disrupting the hypothalamic-pituitary-adrenal axis or prolactin secretion, with moderate and tolerable appetite effects. For most clinical applications, ipamorelin’s superior selectivity profile makes it the preferred choice. GHRP-6 retains value in specific contexts where its potency and appetite-stimulating properties are therapeutically advantageous.